NCT03396211 2023-04-07
A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Elevar Therapeutics
Phase 1 Completed
Clinical Trials
8 trialsNCT01192971 2023-03-03
HCC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT03042611 2022-07-08
ANGEL
Elevar Therapeutics
Phase 3 Completed
NCT03384511 2018-02-20
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Shandong Cancer Hospital and Institute
Phase 4 Completed
NCT01497704 2017-10-02
Dose-Escalation and Safety Trial of YN968D1
Elevar Therapeutics
Phase 1/2 Completed
NCT02836171 2017-02-27
Effect of Itraconazole on the Pharmacokinetics of Apatinib
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02836821 2017-02-27
Effect of Rifampicin on the Pharmacokinetics of Apatinib
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT01270386 2012-02-10
A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed